The WACC of Venus Remedies Ltd (VENUSREM.NS) is 14.7%.
| Range | Selected | |
| Cost of equity | 13.50% - 18.00% | 15.75% |
| Tax rate | 26.10% - 28.30% | 27.20% |
| Cost of debt | 4.00% - 7.50% | 5.75% |
| WACC | 12.5% - 16.8% | 14.7% |
| Category | Low | High |
| Long-term bond rate | 6.9% | 7.4% |
| Equity market risk premium | 8.3% | 9.3% |
| Adjusted beta | 0.8 | 1.09 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 13.50% | 18.00% |
| Tax rate | 26.10% | 28.30% |
| Debt/Equity ratio | 0.1 | 0.1 |
| Cost of debt | 4.00% | 7.50% |
| After-tax WACC | 12.5% | 16.8% |
| Selected WACC | 14.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for VENUSREM.NS:
cost_of_equity (15.75%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (0.8) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.